DK1157023T3 - C-21-modificerede epothiloner - Google Patents

C-21-modificerede epothiloner

Info

Publication number
DK1157023T3
DK1157023T3 DK00910219T DK00910219T DK1157023T3 DK 1157023 T3 DK1157023 T3 DK 1157023T3 DK 00910219 T DK00910219 T DK 00910219T DK 00910219 T DK00910219 T DK 00910219T DK 1157023 T3 DK1157023 T3 DK 1157023T3
Authority
DK
Denmark
Prior art keywords
modified epothilones
epothilones
modified
Prior art date
Application number
DK00910219T
Other languages
Danish (da)
English (en)
Inventor
Gerhard Hoefle
Nicole Glaser
Thomas Leibold
Gregory Vite
Soong-Hoon Kim
Original Assignee
Bristol Myers Squibb Co
Biotechnolog Forschung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Bristol Myers Squibb Co, Biotechnolog Forschung Gmbh filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1157023T3 publication Critical patent/DK1157023T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK00910219T 1999-02-22 2000-02-17 C-21-modificerede epothiloner DK1157023T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone
PCT/US2000/004068 WO2000050423A1 (en) 1999-02-22 2000-02-17 C-21 modified epothilones

Publications (1)

Publication Number Publication Date
DK1157023T3 true DK1157023T3 (da) 2004-03-29

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00910219T DK1157023T3 (da) 1999-02-22 2000-02-17 C-21-modificerede epothiloner

Country Status (37)

Country Link
US (1) US6262094B1 (sk)
EP (1) EP1157023B1 (sk)
JP (1) JP4598957B2 (sk)
KR (1) KR100685336B1 (sk)
CN (1) CN1205208C (sk)
AR (1) AR028815A1 (sk)
AT (1) ATE254615T1 (sk)
AU (1) AU771089B2 (sk)
BG (1) BG64987B1 (sk)
BR (1) BR0008379A (sk)
CA (1) CA2360452C (sk)
CO (1) CO5140093A1 (sk)
CZ (1) CZ301498B6 (sk)
DE (1) DE60006649T2 (sk)
DK (1) DK1157023T3 (sk)
EE (1) EE04852B1 (sk)
ES (1) ES2209831T3 (sk)
GE (1) GEP20033067B (sk)
HK (1) HK1038923B (sk)
HU (1) HUP0200076A3 (sk)
ID (1) ID29829A (sk)
IL (1) IL144501A0 (sk)
LT (1) LT4944B (sk)
LV (1) LV12755B (sk)
MX (1) MXPA01008374A (sk)
MY (1) MY120601A (sk)
NO (1) NO320806B1 (sk)
NZ (1) NZ513629A (sk)
PE (1) PE20001546A1 (sk)
PL (1) PL212545B1 (sk)
PT (1) PT1157023E (sk)
RU (1) RU2253652C2 (sk)
SK (1) SK287200B6 (sk)
TR (1) TR200102401T2 (sk)
TW (1) TWI270546B (sk)
UY (1) UY26024A1 (sk)
WO (1) WO2000050423A1 (sk)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59712968D1 (de) 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
ES2395895T3 (es) * 2000-09-22 2013-02-15 Helmholtz-Zentrum für Infektionsforschung GmbH Triazolo-epotilonas
WO2002030356A2 (en) * 2000-10-13 2002-04-18 The University Of Mississipi Synthesis of epothilones and relates analogs
EP1353667A1 (en) * 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
IL157128A0 (en) * 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
PL363362A1 (en) 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
JP2004529904A (ja) * 2001-03-14 2004-09-30 ブリストル−マイヤーズ　スクイブ　カンパニー 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ
US20060089327A1 (en) * 2002-01-14 2006-04-27 Hohneker John A Combinations comprising epothilones and anti-metabolites
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
US6900331B2 (en) * 2002-03-01 2005-05-31 University Of Notre Dame Derivatives of epothilone B and D and synthesis thereof
JP2005522461A (ja) * 2002-03-08 2005-07-28 ノバルティス　アクチエンゲゼルシャフト エポチロン誘導体およびアルキル化剤を含む組合せ剤
SI1485090T1 (sl) * 2002-03-08 2008-06-30 Novartis Ag Kombinacija vključujoča derivat epotilona in imidazotetrazinon
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
DK1483251T3 (da) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
KR20040106422A (ko) * 2002-05-01 2004-12-17 노파르티스 아게 간암 및 다른 암 질병 치료용 에포틸론 유도체
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
NZ538522A (en) 2002-08-23 2008-03-28 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto, analogues and uses thereof
BRPI0314133A8 (pt) 2002-09-23 2017-09-19 Bristol Myers Squibb Co Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona
AU2003279923A1 (en) * 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Epo D + 5-FU/GEMCITABINE
ES2349532T3 (es) 2003-02-06 2011-01-04 Bristol-Myers Squibb Company Compuestos basados en tiazolilo útiles como inhibidores de cinasa.
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
PL1817013T3 (pl) * 2004-11-18 2009-01-30 Bristol Myers Squibb Co Dojelitowa powlekana peletka zawierająca Ixabepilone
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
US8003801B2 (en) * 2005-11-22 2011-08-23 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
US8143415B2 (en) * 2007-05-25 2012-03-27 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
EP2962731A1 (en) 2008-01-08 2016-01-06 Bristol-Myers Squibb Company Combination of ipilimumab and paclitaxel for the treatment of cancer
KR20100137576A (ko) * 2008-04-24 2010-12-30 브리스톨-마이어스 스큅 컴퍼니 알츠하이머병을 포함하는 타우-관련 질병의 치료에서의 에포틸론 ｄ의 용도
JP2011525616A (ja) * 2008-05-29 2011-09-22 ブリストル−マイヤーズ スクイブ カンパニー 共刺激経路の調節に対する患者応答を予測するための方法
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
KR101733255B1 (ko) 2009-07-20 2017-05-08 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 상승작용적 치료를 위한 항­ｃｔｌａ４ 항체와 다양한 치료 요법의 조합
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
MY173795A (en) 2009-11-05 2020-02-24 Incozen Therapeutics Pvt Ltd Novel benzopyran kinase modulators
ES2625637T3 (es) 2010-02-12 2017-07-20 Pharmascience Inc. Compuestos de unión al dominio BIR IAP
EA025281B9 (ru) 2010-05-17 2017-08-31 Инкозен Терапьютикс Пвт. Лтд. СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
SI2705029T1 (sl) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S.A. Nove spojine kot modulatori protein-kinaz
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
JP6192708B2 (ja) 2012-03-30 2017-09-06 ライゼン・ファーマシューティカルズ・エスアー Ｃ−ｍｅｔプロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
EP2972394A4 (en) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
EP3227335A1 (en) 2014-12-04 2017-10-11 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
DK3313528T3 (da) 2015-06-29 2021-09-20 Bristol Myers Squibb Co Immunterapeutiske doseringsskemaer omfattende pomalidomid og et anti-cs1-antistof til behandling af cancer
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE301115C (sk)
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
ATE261961T1 (de) 1995-11-17 2004-04-15 Biotechnolog Forschung Gmbh Epothilon-derivate, ihre herstellung und verwendung
EP0923583A1 (de) 1996-08-30 1999-06-23 Novartis AG Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE59712968D1 (de) * 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
WO1998038192A1 (de) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
ATE224882T1 (de) 1997-07-16 2002-10-15 Schering Ag Thiazolderivate, verfahren zur herstellung und verwendung
AU9340998A (en) 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
JP2002533114A (ja) * 1998-12-23 2002-10-08 ブリストル−マイヤーズ スクイブ カンパニー エポチロン製造のための微生物形質転換法

Also Published As

Publication number Publication date
EP1157023A1 (en) 2001-11-28
IL144501A0 (en) 2002-05-23
LT2001086A (en) 2002-04-25
KR100685336B1 (ko) 2007-02-23
PT1157023E (pt) 2004-03-31
AU771089B2 (en) 2004-03-11
ID29829A (id) 2001-10-11
WO2000050423A1 (en) 2000-08-31
EE200100437A (et) 2002-12-16
MXPA01008374A (es) 2003-06-06
TR200102401T2 (tr) 2001-12-21
LT4944B (lt) 2002-08-26
EP1157023B1 (en) 2003-11-19
AR028815A1 (es) 2003-05-28
DE60006649D1 (de) 2003-12-24
NO20014017L (no) 2001-10-17
HK1038923B (zh) 2004-03-19
CO5140093A1 (es) 2002-03-22
NZ513629A (en) 2004-01-30
BG105830A (en) 2002-03-29
DE60006649T2 (de) 2004-09-30
PL212545B1 (pl) 2012-10-31
AU3234800A (en) 2000-09-14
HK1038923A1 (en) 2002-04-04
NO320806B1 (no) 2006-01-30
PL350179A1 (en) 2002-11-18
ATE254615T1 (de) 2003-12-15
PE20001546A1 (es) 2001-03-18
HUP0200076A2 (hu) 2002-12-28
LV12755B (lv) 2002-04-20
US6262094B1 (en) 2001-07-17
UY26024A1 (es) 2000-09-29
CA2360452A1 (en) 2000-08-31
KR20010102199A (ko) 2001-11-15
EE04852B1 (et) 2007-06-15
TWI270546B (en) 2007-01-11
CZ301498B6 (cs) 2010-03-24
JP4598957B2 (ja) 2010-12-15
SK10782001A3 (sk) 2002-03-05
CN1205208C (zh) 2005-06-08
NO20014017D0 (no) 2001-08-17
JP2002537395A (ja) 2002-11-05
ES2209831T3 (es) 2004-07-01
BR0008379A (pt) 2002-09-24
LV12755A (en) 2001-11-20
GEP20033067B (en) 2003-09-25
CN1341114A (zh) 2002-03-20
CZ20012991A3 (cs) 2002-01-16
SK287200B6 (sk) 2010-03-08
BG64987B1 (bg) 2006-11-30
RU2253652C2 (ru) 2005-06-10
MY120601A (en) 2005-11-30
CA2360452C (en) 2011-07-26
HUP0200076A3 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
DK1157023T3 (da) C-21-modificerede epothiloner
IS5381A (is) 4-fenyl-pyridin afleiður
DE60044873D1 (de) Orientierte biopolymermembrane
NO20021077L (no) Amino-triazolopyridin-derivater
DE60009747D1 (de) Admantan-derivate
DE50002558D1 (de) Rückspülfiltervorrichtung
DE50010060D1 (de) Thiazolylamid-derivate
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
NO20021803L (no) Isoksazolkarboksamid-derivater
ATE257148T1 (de) Propargyletherderivate
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
DK1218340T3 (da) 4-hydroxybiphenylhydrazid-derivater
ATE293592T1 (de) Resorcinderivate
NO20020212L (no) 3-amino-2-benzyl-1-fenyl-propanderivater
NO20022867D0 (no) Syklopentenon-derivater
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
ATE269328T1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate